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Background: Breast cancer is the most common cancer in the Arab world and it ranked first among Saudi females.
Doxorubicin (DOX), an anthracycline antibiotic is one of the most effective anticancer agents used to treat breast
cancer. chronic cardiotoxicity is a major limiting factor of the use of doxorubicin. Therefore, our study was designed
to assess the role of a natural product resveratrol (RSVL) on sensitization of human breast cancer cells (MCF-7) to
the action of DOX in an attempt to minimize doxorubicin effective dose and thereby its side effects.
Methods: Human breast cancer cell line MCF-7, was used in this study. Cytotoxic activity of DOX was determined
using (sulforhodamine) SRB method. Apoptotic cells were quantified after treatment by annexin V-FITC- propidium
iodide (PI) double staining using flow-cytometer. Cell cycle disturbance and doxorubicin uptake were determined
after RSVL or DOX treatment.
Results: Treatment of MCF-7 cells with 15 μg/ml RSVL either simultaneously or 24 h before DOX increased the
cytotoxicity of DOX, with IC50 were 0.056 and 0.035 μg/ml, respectively compared to DOX alone IC50 (0.417 μg/ml).
Moreover, flow cytometric analysis of the MCF-7 cells treated simultaneously with DOX (0.5 μg/ml) and RSVL
showed enhanced arrest of the cells in G0 (80%). On the other hand, when RSVL is given 24 h before DOX
although there was more increased in the cytotoxic effect of DOX against the growth of the cells, however, there
was decreased in percentage arrest of cells in G0, less inhibition of DOX-induced apoptosis and reduced DOX
cellular uptake into the cells.
Conclusion: RSVL treatment increased the cytotoxic activity of DOX against the growth of human breast cancer
cells when given either simultaneously or 24 h before DOX.
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Breast cancer is the leading cause of death in women
worldwide and it is the most common cancer in the Arab
world. It affects women at an early age compared with
women in western countries [1]. Doxorubicin (DOX), an
anthracycline antibiotic is among the most effective
anticancer agents used to treat breast cancer [2]. It exerts
its cytotoxic effect by intercalating between DNA base
pairs on the double helix and inhibiting topoisomerase
II (TOPO-II), the enzyme responsible for DNA helix* Correspondence: moneimosman@hotmail.com
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reproduction in any medium, provided the orconformation and stability. Unfortunately, chronic cardi-
otoxicity including development of a cardiomyopathy is a
major limiting factor of the chemotherapeutic use of
doxorubicin [3]. In an attempt to minimize DOX effect-
ive chemotherapeutic dose and thereby its side effects, a
variety of approaches have been Investigated. One of
them is the search for natural compounds with chemo-
preventive or anticancer properties that can be used
in combination with doxorubicin. Resveratrol (RSVL)
(trans – 3, 5, 4 – trihydroxystilbene) is a naturaly occur-
ring poly-phenolic compound found primarily in root
extracts of the oriental plant Polygonum cuspidatum and
many other plant species [4]. It is highly abundant in
skins of red grapes and moderately abundant in peanuts
and blueberries [4]. It has recently been discovered that itLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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systems, which include anti-inflammatory, antioxidant,
anti-neoplastic, anti-carcinogenic, anti-tumorigenic, cardio-
protective, neuroprotective, anti-aging and antiviral effects
[4]. Its potential chemopreventive and chemotherapeutic
activities have been demonstrated in all three stages of car-
cinogenesis (initiation, promotion, and progression) [5].
Resveratrol exhibits anticancer properties in a wide variety
of tumor cells, including breast cancer cells [6]. The
growth-inhibitory effect of RSVL is mediated through dif-
ferent mechanisms [7]. Therefore this study was aimed to
explore whether the natural product resveratrol could en-
hance the cytotoxic effect of DOX against the growth of
human breast cancer cell line (MCF-7 cell line). We investi-
gated the possible mechanisms of interaction between
DOX and RSVL regarding DOX cytotoxicity, apoptosis in-
duction, cellular uptake and cell cycle progression of breast
cancer cells in presence and absence of RSVL.
Materials and methods
Drugs and chemicals
DOX hydrochloride and RSVL were purchased from
Sigma Aldrich (St. Louis, Mo, USA). The stock solutions
of both drugs were dissolved in phosphate buffered sa-
line (PBS) and preserved at –20°C. The solution was
diluted in Dullbecco’s modified Eagles medium (DMEM)
or PBS immediately before each experiment to the
desired final concentrations. Dullbecco’s modified eagles
medium (DMEM), Trypsin/EDTA, Phosphate buffered
saline (PBS), Penicillin G and Steptomycin antibiotics,
Acetic acid, Trizma base, SulphoRhodamine- B (SRB),
Propidium Iodide (PI) and Annexin V-FITC apoptosis
detection kit were purchased from Sigma Aldrich Co.
Cells and cell cultures
Human breast cancer cell line MCF-7, was used in this
study. It was obtained from National Cancer Institute,
Cairo University, Egypt.
The adherent cells were grown as “monolayer culture”
in DMEM supplemented with Penicillin (100 IU/ml),
Streptomycin (100 μg/ml) and 10% Fetal bovine serum.
Cells were cultured at 37°C in a humidified 5% CO2 at-
mosphere and were passaged every 4–5 days.
Methods
Assessment of cytotoxic activity
Cytotoxicity was determined using (sulforhodamine)
SRB method as previously described by Skehan et al.
[8]. Cells were seeded in 96 well microtiter plates at a
concentration of 30 × cells/well in DMEM supplemen-
ted medium. After 24 h, cells were incubated for add-
itional 48 h with various concentrations of DOX and
RSVL in the following ranges: 0.0312–5 μg/ml for DOX
and 15 μg/ml for RSVL. Drugs were added either in asimultaneous or sequential manner. In sequential treat-
ment, the cells were pretreated with RSVL for 24 h, and
then followed by DOX for further 48 h. Cells were fixed
in situ by adding 50 μL of cold 50% TCA for 1 h at 4°C.
the supernatant is then discarded, and the wells were
washed five times with distilled water, air dried, stained
for 30 min at room temperature with 0.4% SRB dis-
solved in 1% acetic acid and then washed four times
with 1% acetic acid. The plates were air dried and the
dye was solubilized with 100 μl/well of 10 mM Tris base
(PH 10.5) for 10 min. The optical density (OD) was
obtained using ELx808 Absorbance Microplate Reader
obtained from BioTek Instruments,Inc (Winooski,VT,
U.S.A.) at wavelength of (490–530 nm).
Surviving fraction
¼ Optical density of treated cells
Optical density of untreated control cells
IC50 (the concentration of DOX necessary to produce
50% inhibition of cell growth) was calculated from linear
equation of the survival fraction curve.
Y ¼ m Xþ b
Where:
Y = 0.5 (the surviving fraction when there is a 50%
inhibition of cell growth).
m = the slope.
X = dose of DOX induces 50% inhibition.
b = the y-intercept.
Flow-cytometric assay of apoptosis
Apoptotic cells were quantified by Annexin V-FITC-
Propidium iodide (PI) double staining, using an Annexin
V-FITC apoptosis detection kit according to the method
of Van Engeland et al. [9]. Cells were seeded in 12-well
plates at cell density of 6–8 × cells/well in DMEM sup-
plemented medium. Twenty four hours later, cells were
incubated for additional 48 h with 15 μg/ml RSVL and
various concentrations of DOX in the following range:
0.25–0.5 μg/ml. Drugs were added in a simultaneous or
sequential manner. In sequential treatment, the cells
were pretreated with RSVL for 24 h, and then followed
by DOX for additional 48 h. Cell medium was then
removed and the wells were washed with PBS, then the
cells were harvested with trypsin/EDTA. Cells were
washed once with PBS following trypsinization, resus-
pended in 1 ml of Binding Buffer. Annexin V FITC Conju-
gate were added to the cells according to manufacturer’s
instructions for 10 min at room temperature while pro-
tected from light. Fluorescence of the cells was read imme-
diately by flow cytometer (NAVIOS Beckman Coulter,
U.S.A.).










0.0625 0.97 ± 0.17 0.10a ± 0.013 0.173a ± 0.03
0.25 0.92 ± 0.112 0.091a ± 0.018 0.124a ± 0.006
0.5 0.29 ± 0.061 0.089a ± 0.034 0.047a,b± 0.003
Each data is the mean ± S.E.M of two experiments each one in duplicate.
aSignificantly different from DOX at P-value < 0.05.
b Significantly different from simultaneous DOX+RSVL at P-value < 0.01.
Table 2 Effect of DOX and/or RSVL on the growth of
MCF-7 cells
Treatment IC50 (μg/ml)
DOX 0.417 ± 0.107
DOX + RSVL (15 μg/ml)
(supplied simultaneously)
0.056a ± 0.026
DOX + RSVL (15 μg/ml)
(RSVL supplied 24 h before DOX)
0.035a,b ± 0.016
IC50: the concentration of DOX necessary to produce 50% inhibition of cell
growth.
a Significantly different from DOX at P-value < 0.05.
b Significantly different from DOX+ RSVL (Simultaneously) at P-value < 0.05.
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Cells were plated in 12-well plates at cell density of 6–
8×105 cells/well in DMEM supplemented medium.
Twenty four hours later, cells were incubated for add-
itional 48 h with 15 μg/ml RSVL and a various
concentrations of DOX in the following range: 0.125–0.5
μg/. Drugs were added in a simultaneous or sequential
manner. In sequential treatment, the cells were pretreated
with RSVL for 24 h, and then followed by DOX for 48 h.
Cell medium was then removed and the wells were
washed once with PBS. Cell cycle analysis was performed
according to the method of Pozarowski and Darzynkie-
wicz, [10].
The cells were harvested with trypsin/EDTA, washed
once with PBS and then resuspended in 0.5 ml of 0.05%
Triton X-100 for 10 min at room temperature. Stai
ning of cellular DNA was performed by adding 1 ml of
50 μg/mL PI to each cell suspension for 20 min at room
temperature. Cell cycle analysis was performed by using
flow cytometer (Becton Dicknoson (BD) FACSCalbur,
USA).
Assessment of doxorubicin cellular accumulation
DOX cellular accumulation assessment in MCF-7 cells
was performed using spectrofluorometer (F-2000 Fluor-
escence spectrophotometer Hitachi, Japan) according to
the method of Kitagawa et al. [11]. DOX fluorescence
intensity was measured at excitation and emission wave-
lengths of λ ex = 496 nm and λ em = 592 nm, respect-
ively to determine DOX concentration.
DOX cellular accumulation ratio
¼ DOX concentration in RSVL treated cells
DOX concentration in cells treated with DOX alone
Statistical analysis
Statistical analysis was performed using SPSS (statistical
package of social sciences, version 16). One way analysis
of variance (ANOVA) followed by least significant differ-
ence (LSD) for post hoc analysis, was used for multiple
comparisons. Statistical significance was acceptable to a
level of p < 0.05.
Results
Effect of RSVL treatment on the cytotoxic activity of DOX
Cytotoxicity was expressed as the percentage of surviving
fraction compared with untreated control cells (Tables 1
and 2). Treatment with DOX alone showed IC50 (the
concentration necessary to produce 50% inhibition of cell
growth) value of 0.417 μg/ml. Simultaneous addition of
15 μg/ml RSVL with or 24 h before DOX was found to
sensitize MCF-7 cells to the cytotoxic effect of DOX.,
IC50 were 0.056 μg/ml and 0.035 μg/ml, respectively,which were significantly different from DOX alone. At
the same time RSVL 24 before DOX showed IC50 value
significantly different from DOX+RESVL supplied
simultaneously.Effect of RSVL and DOX treatment on apoptosis induction
Apoptosis was determined by flow cytometry in MCF-7
cells that have been stained with FITC-annexin V and
PI. Percentages of cells in each quadrant in Figures 1
and 2 are representative of: (C1) necrosis, (C2) late
apoptosis, (C3) live cells, and (C4) early apoptosis.
Figure 1 shows control MCF-7 cells (A), cells treated
with 15 μg/ml RSVL (B) and cells treated with 0.5 μg/ml
DOX alone (C) or in the presence of 15 μg/ml RSVL
given simultaneously with 0.5 μg/ml DOX (D) or 24 h
before it (E). Figure 2 showed cells treated with 0.25
μg/ml DOX alone (F) or in the presence of 15 μg/ml
RSVL given simultaneously with 0.25 μg/ml DOX (G) or
24 h before it (H).
The percentage of early apoptotic cells (Annexin V-
positive cells) were dramatically increased after treat-
ment with DOX or DOX + RSVL in comparison to the
control cells (1.3% early apoptotic cells). Treatment with
0.25 μg/ml DOX showed 76.1% of early apoptotic cells.
While combination treatment of 0.25 μg/ml DOX with
15 μg/ml RSVL simultaneously or RSVL 24 h before
DOX showed 91.2%, and 76.1% of early apoptotic cells,
respectively (Figure 3).
Figure 1 Effect of DOX and/or RSVL on apoptosis induction in MCF-7 cells. Apoptosis was analyzed after 48 h of exposure to drugs by
staining with propidium iodide (PI, y-axis) and annexin- FITC (x-axis). (A) control, (B) cells treated with 15 μg/ml RSVL, (C) cells treated with
0.25 μg/ml DOX, (D) cells treated with 0.25 μg/ml DOX and RSVL 15 μg/ml in simultaneous manner, (E) cells treated with 0.25 μg/ml DOX and
RSVL 15 μg/ml given 24 h before DOX. The percentage of cells in each quadrant are indicated (C1: necrosis, C2: late apoptosis, C3: live cells, C4:
early apoptosis). The experiment was repeated twice each one in duplicate.
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progression of MCF-7
Treatment with different concentrations of DOX (0.125,
0.25 and 0.5 μg/ml), showed a preferential block of MCF-
7 cells in S phase (data not shown). DOX concentration
increased cell accumulation in S phase to 8.41% and
10.9% at dose level of 0.25 and 0.5 ug/ml,respectively
(Figure 3) compared with cells in G1 phase. Treatment
with 15 μg/ml RSVL showed arrest of cells in G0 and Sphases compared with G1 phase cells 44.53% and 8.82%,
respectively (Figure 4).
Combination treatment of DOX 0.25 μg/ml with
15 μg/ml RSVL simultaneously showed a huge increase
in the percentages of cells in G0 phase in comparison
with G1 phase cells. The cell accumulation percentage at
G0 phase was 79.77% when treated with 0.25 μg/ml DOX
given simultaneously with 15 μg/ml RSVL (Figure 4).
Combination treatment of the same concentration of
Figure 2 Effect of 0.25 μg/ml DOX and/or RSVL on apoptosis induction in MCF-7 cells. Apoptosis was analyzed after 48 h of exposure to
drugs. Each point is the mean ± S.E.M of two experiments each one in duplicate. * Significantly different from control at P-value < 0.05.
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also showed an increase in the percentages of cells in G0
phase compared with G1 phase cells but the increase was
less than that observed after the simultaneous trearment.
The cell accumulation percentages at G0 phase were
58.61% for cells treated with 15 μg/ml of RSVL fol-
lowed by 0.25 μg/ml DOX after 24 h, (Figure 4).Figure 3 Effect of 0.25 μg/ml DOX and/or RSVL on cell cycle phase di
48 h of exposure to drugs by staining with propidium iodide (PI). Each poi
* Significantly different from the corresponding DOX-induced Go arrest at
induced G1 arrest at P-value < 0.05.Effect of RSVL on doxorubicin cellular accumulation
MCF-7 cells were treated with different concentrations
of DOX (0.125, 0.25 and 0.5 μg/ml) in the presence or
absence of 15 μg/ml RSVL given simultaneously or 24 h
before DOX.
Table 3 showed DOX cellular uptake concentrations after
treatment with DOX alone, DOX+RSVL (simultaneously)stribution of MCF-7 cells. Cell cycle distribution was analyzed after
nt is the mean ± S.E.M of two experiments each one in duplicate.
P-value < 0.05. # Significantly different from the corresponding DOX-
Figure 4 Effect of RSVL supplied either simultaneously or 24 h before 0.5 μg/ml DOX on DOX cellular uptake in MCF-7 cells. DOX
accumulation ratio was calculated after 48 h of exposure to drugs as seen in materials and methods (3.2.4.3). Each data is the mean ± S.E.M of
two experiments each one in duplicate. * Significantly different from DOX+RSVL (24 h before) at P-value < 0.05.
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cellular uptake concentrations were 0.022, 0.027 and 0.041
μg/6 × cells in MCF-7 cells treated with 0.125, 0.25 and 0.5
μg/ml DOX, respectively.
Table 3 and Figure 4 showed that RSVL treatment
simultaneously with DOX increased its cellular accumu-
lation gradually. The accumulation ratio was 1.58 when
cells treated with 0.5 μg/ml DOX simultaneously with
15 μg/ml RSVL, respectively.
Contrary to the above results, in MCF-7 cells that
were pre-treated with 15 μg/ml RSVL 24 h before the
cellular accumulation ratio was 0.58 compared with 1.58
when cells treated with 0.5 μg/ml DOX after 24 h of
treatment with 15 μg/ml (Figure 4).
Discussion
Doxorubicin is the most widely used drug in the treat-
ment of a variety of human neoplasms, However, with
the increasing use of DOX, acute as well as chronic cu-
mulative dose-dependent cardiomyopathy has been
recognized as the major limiting factor for DOX chemo-
therapy [12,13]. Therefore, in this study we investigated
the modulatory effect of the natural polyphenolic com-
pound, RSVL on DOX cytotoxicity in MCF-7 human
breast cancer cell line.Table 3 Effect of RSVL treatment on the cellular uptake
of DOX in MCF-7 cells





DOX (0.5 μg/ml) 0.041 ± 0.008 0.062 a ± 0.011 0.023 ± 0.001
DOX (0.25 μg/ml) 0.027 ± 0.004 0.031 ± 0.005 0.024 ± 0.001
DOX (0.125 μg/ml) 0.022 ± 0.004 0.021 ± 0.004 0.013 ± 0.002
Each data is the mean ± S.E.M of two experiments each one in duplicate.
aSignificantly different from DOX at P-value < 0.05.Treatment of MCF-7 cells with different DOX doses
alone was observed to be cytotoxic to the cells. The
cytotoxicity of DOX has been confirmed by the results
of induction of apoptosis and cell cycle progression,
where 0.25 μg/ml DOX induced 49 –fold increase in
early apoptotis and 2-fold increase in arrest of the cells
in S phase in comparison with control cells.
Similar results was obtained following single treatment
of DOX in MCF-7 cells [14]. In support of the import-
ance of cell-cycle arrest to DOX cytotoxicity, it has been
found that P388 leukemia cells synchronized in S and
G2/M phases were more sensitive to DOX than cells in
G1 phase [15]. Our results, have further confirmed the
fact that anthracyclines are mostly active on proliferating
cells in S and G2/M phases due to the maximal expres-
sion of their target enzyme TOPO II at these phases
[16,17].
Resveratrol is known to have both cardioprotective
and antitumor activities [7,18] and it can attenuate
DOX-induced early cellular damage in cancer patients
[19]. Thus RSVL is a perfect candidate to be used as a
sensitizing agent to modulate the cytotoxic effect of
DOX against the growth of breast cancer cells. We also
observed that, MCF-7 cells treated with RSVL alone
showed high increase in early apoptosis, S-phase and in
G0 phase (Figures 2 and 3). Resveratrol has previously
been shown to induce dose-dependent cell cycle arrest,
growth inhibition or apoptosis in several human cancer
cell lines [20]. Resveratrol apoptosis induction effect in
tumor cell line from different origins was shown to be
through a lot of different regulatory mechanisms [21,22].
Previous studies on the effects of RSVL on the cell cycle
of many cell lines including MCF-7 cells, demonstrated
the ability of RSVL to block the S–G2 transition result-
ing in a concentration-dependent accumulation of cells
in S or G1 phase which may be due to inhibition of the
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tide reductase [20,23-25]. Other mechanisms that could
explain RSVL-induced S phase arrest is the increase ex-
pression of p53, a tumor suppressor protein [26], the in-
crease expression of positive G1/S regulators, such as
cyclin D1 and cyclin E which are responsible for S phase
entry [27], depletion of survivin, an inhibitor of apop-
tosis protein [7]. Resveratrol-induced S phase arrest
would eventually lead to apoptotic death as indicated by
the very high increase in G0 phase arrest (Figure 3).
Treatment with 15 μg/ml RSVL supplied simultan-
eously with different DOX concentrations enhanced the
cytotoxic effect of DOX significantly. There was a 7.4-
fold decrease in IC50 in cells treated with DOX and
RSVL simultaneously as compared with DOX treated
cells (Table 2). To gain further insight into the inter-
action mechanisms between DOX and RSVL, apoptosis
assay, flow cytometric DNA analysis and DOX cellular
uptake assay were performed. Apoptosis assay showed a
small increase of the early apoptotic cell percentages in
the simultaneous treated cells as compared with DOX
treated group. The smaller DOX dose used simultan-
eously with RSVL showed a stronger increase in apop-
tosis as compared with DOX treated group (Figure 2).
Furthermore, flow cytometric analysis revealed that sim-
ultaneous treatment of DOX with RSVL induced prefer-
ential cell arrest at G0, there were 41-fold increase in
percentages of G0 phase arrest for treated cells (Figure 3).
Several studies have reported that RSVL molecular
mechanisms of sensitization for drug induced apoptosis
involved cell cycle arrest in S phase [27,28], which has
been used as a strategy to increase drug incorporation
into cells. Thus, the cooperative effect of RSVL and the
cell cycle-dependent drug DOX may result from RSVL-
induced cell cycle arrest in S phase, thereby exposing a
higher proportion of tumor cell population to DOX,
therefore, more cells will undergo apoptosis and leave
the cycle to enter the apoptotic G0 phase.
These findings have been further confirmed by the
observed increased in DOX cellular uptake after the sim-
ultaneous treatment with RSVL, which was in a dose
dependent manner. There were an increase in DOX accu-
mulation ratios for cells treated with DOX and RSVL,
(Figure 4). This implies that, RSVL not only exposed
higher proportion of MCF-7 cells to DOX by inducing cell
cycle arrest in S phase but it also increased the DOX con-
centration available inside the cells. The increase in DOX
cellular uptake inside the MCF-7 cells may be explained
based on the inhibition of P-glycoprotein and multidrug
resistance (MDR) [29] that plays very important role in
the absorption, distribution, and elimination of DOX, and
thus determines its efficacy and toxicity [29,30]. Surpris-
ingly our results showed that when RSVL was given prior
to DOX, although it was more cytotoxic against thegrowth of MCF-7 cells, we noticed slight inhibition of
DOX-induced apoptosis, less percentage of cells arrest in
G0 and decreased DOX cellular uptake into the cells com-
pared with simultaneous treatment with DOX and RSVL.
The decrease of DOX cellular uptake in MCF-7 cells
and the arrest of cells in S phase suggest that the
enhanced growth inhibitory effects observed after the se-
quential RSVL and DOX treatment may not be caused
by the synergism between DOX and RSVL or by the
increased DOX cellular uptake, but this may be caused
by the cytotoxic activity of RSVL itself [20,27].
Recently (2012), RSVL was found to reduce the intra-
cellular accumulation of rhodamine 123 in colon cancer
cell line suggesting that RSVL enhances the activity of P-
glycoprotein [31]. These conflicting findings could be
explained on the following basis: MDR can be acquired
after initial exposure to the anticancer drugs [32]. In
addition several studies have found that some of the well
known P-glycoprotein antagonists such as verapamil and
cyclosporine A can induce P-glycoprotein expression in
colon carcinoma cells [33]. It is important to note
that the time needed for expression and inhibition of
P-glycoprotein by their antagonists is controversial.
Therefore, based on our results we can say that RSVL
antagonizes or inhibits P-glycoprotein when it is given
simultaneously with DOX thereby causing an increase
in DOX cellular uptake [29]. However, when it is given
24 h before DOX it enhances the P-glycoprotein expres-
sion. The 24 h period between RSVL and DOX is con-
sidered as an intial exposure that will enhance the
expression of P glycoprotein and thereby MDR that will
lead to the decrease in DOX cellular uptake. Further
studies are needed to investigate how different sequence
of treatment of RSVL and DOX could affect the P-
glycoprotein activity and hence by the DOX intracellular
accumulation in MCF-7 cells.
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